Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion

References

• ScherJUPillingerMH15d-PGJ2: the anti-inflammatory prostaglandin?Clin Immunol2005114210010915639643
   PubMed Web of Science ®Google Scholar
• GilroyDWColville-NashPRWillisDChiversJPaul-ClarkMJWilloughbyDAInducible cyclooxygenase may have anti-inflammatory propertiesNat Med19995669870110371510
   PubMed Web of Science ®Google Scholar
• KimEHSurhYJ15-deoxy-Delta12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factorsBiochem Pharmacol200672111516152816987499
   PubMed Web of Science ®Google Scholar
• FormanBMTontonozPChenJBrunRPSpiegelmanBMEvansRM15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gammaCell19958358038128521497
   PubMed Web of Science ®Google Scholar
• KliewerSALenhardJMWillsonTMPatelIMorrisDCLehmannJMA prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiationCell19958358138198521498
   PubMed Web of Science ®Google Scholar
• RossiAKapahiPNatoliGAnti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinaseNature2000403676510310810638762
   PubMed Web of Science ®Google Scholar
• ChenSLiuCWangXLiXChenYTangN15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) promotes apoptosis of HBx-positive liver cellsChem Biol Interact2014214263224582817
   PubMed Web of Science ®Google Scholar
• FarrowBSugiyamaYChenAUffortENealonWMark EversBInflammatory mechanisms contributing to pancreatic cancer developmentAnn Surg20042396763769 discussion 769–77115166955
   PubMed Web of Science ®Google Scholar
• KawahitoYKondoMTsubouchiY15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in ratsJ Clin Invest2000106218919710903334
   PubMed Web of Science ®Google Scholar
• EmiMMaeyamaKThe biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cellsBiochem Pharmacol20046771259126715013841
   PubMed Web of Science ®Google Scholar
• BureauFDesmetCMélotteDA proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibitionJ Immunol2002168105318532511994490
   PubMed Web of Science ®Google Scholar
• MartinezAESanchez-GomezFJDiez-DacalBOesteCLPerez-SalaD15-Deoxy-delta(12,14)-prostaglandin J2 exerts pro- and anti-inflammatory effects in mesangial cells in a concentration-dependent mannerInflamm Allergy Drug Targets2012111586522309084
   PubMedGoogle Scholar
• PowellWS15-Deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product?J Clin Invest2003112682883012975467
   PubMed Web of Science ®Google Scholar
• OlivaJLPérez-SalaDCastrilloAThe cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-RasProc Natl Acad Sci U S A200310084772477712684535
   PubMed Web of Science ®Google Scholar
• UekiSKatoHKobayashiYAnti- and proinflammatory effects of 15-deoxy-delta-prostaglandin J2(15d-PGJ2) on human eosinophil functionsInt Arch Allergy Immunol2007143suppl 1152217541271
   PubMedGoogle Scholar
• ZhangXYoungHAPPAR and immune system – what do we know?Int Immunopharmacol2002281029104412349941
   PubMed Web of Science ®Google Scholar
• ChuderlandDSegerRCalcium regulates ERK signaling by modulating its protein-protein interactionsCommun Integr Biol2008114519704446
   PubMedGoogle Scholar
• AgellNBachsORocamoraNVillalongaPModulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulinCell Signal200214864965412020764
   PubMed Web of Science ®Google Scholar
• NapimogaMHda SilvaCACarregaroVExogenous administration of 15d-PGJ2-loaded nanocapsules inhibits bone resorption in a mouse periodontitis modelJ Immunol201218921043105222706081
   PubMed Web of Science ®Google Scholar
• Homem de BittencourtPIJrLagranhaDJMaslinkiewiczALipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesionsAtherosclerosis2007193224525816996518
   PubMed Web of Science ®Google Scholar
• HagensWIMattosAGreupinkRTargeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluatedPharm Res200724356657417245650
   PubMed Web of Science ®Google Scholar
• ChimeSAKenechukwuFCAttamaAANanoemulsions – advances in formulation, characterization and applications in drug deliverySezerADApplication of Nanotechnology in Drug DeliveryRijekaInTech201477126
   Google Scholar
• McClementsDJNanoemulsions versus microemulsions: terminology, differences, and similaritiesSoft Matter20128617191729
   Web of Science ®Google Scholar
• FukushimaSKishimotoSTakeuchiYFukushimaMPreparation and evaluation of o/w type emulsions containing antitumor prostaglandinAdv Drug Deliv Rev2000451657511104898
   PubMed Web of Science ®Google Scholar
• YamaguchiTFukushimaYItaiSHayashiHRate of release and retentivity of prostaglandin E1 in lipid emulsionBiochim Biophys Acta1995125633813867786903
   PubMed Web of Science ®Google Scholar
• MizushimaYHoshiKReview: recent advances in lipid microsphere technology for targeting prostaglandin deliveryJ Drug Target199312931008069557
   PubMed Web of Science ®Google Scholar
• zur MuhlenASchwarzCMehnertWSolid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanismEur J Pharm Biopharm19984521491559704911
   PubMed Web of Science ®Google Scholar
• RaggiCMousaHSCorrentiMSicaAInvernizziPCancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategiesOncogene201635667168225961921
   PubMed Web of Science ®Google Scholar
• SchultzeJLReprogramming of macrophages-new opportunities for therapeutic targetingCurr Opin Pharmacol201626101526426255
   PubMed Web of Science ®Google Scholar
• SchusterVLProstaglandin transportProstaglandins Other Lipid Mediat200268–69633647
   PubMed Web of Science ®Google Scholar
• HarrisSGPadillaJKoumasLRayDPhippsRPProstaglandins as modulators of immunityTrends Immunol200223314415011864843
   PubMed Web of Science ®Google Scholar
• NarumiyaSFukushimaMSite and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibitionJ Pharmacol Exp Ther198623925005053772804
   PubMed Web of Science ®Google Scholar
• YameenBChoiWIVilosCSwamiAShiJFarokhzadOCInsight into nanoparticle cellular uptake and intracellular targetingJ Control Release201419048549924984011
   PubMed Web of Science ®Google Scholar
• HatakeyamaHAkitaHHarashimaHThe polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumorsBiol Pharm Bull201336689289923727912
   PubMed Web of Science ®Google Scholar
• LiuFLiuDLong-circulating emulsions (oil-in-water) as carriers for lipophilic drugsPharm Res1995127106010647494803
   PubMed Web of Science ®Google Scholar
• OhJYGilesNLandarADarley-UsmarVAccumulation of 15-deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence inductionBiochem J2008411229730618237271
   PubMedGoogle Scholar
• TeagardenDLAndersonBDPetreWJDetermination of the pH-dependent phase distribution of prostaglandin E1 in a lipid emulsion by ultrafiltrationPharm Res1988584824873244655
   PubMed Web of Science ®Google Scholar
• YamaguchiTTanabeNFukushimaYNasuTHayashiHDistribution of prostaglandin E1 in lipid emulsion in relation to release rate from lipid particlesChem Pharm Bull1994423646650
   Web of Science ®Google Scholar